These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 39315101)

  • 21. Immunological characterisation and immunoprotective efficacy of functional domain antigens of botulinum neurotoxin serotype A.
    Liu FJ; Shi DY; Mao YY; Xiong XH; Lu JS; Pang XB; Dong XJ; Yang ZX; Yu YZ
    Vaccine; 2020 Mar; 38(14):2978-2983. PubMed ID: 32113807
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.
    Sharma R; Zhao H; Al-Saleem FH; Ubaid AS; Puligedda RD; Segan AT; Lindorfer MA; Bermudez R; Elias M; Adekar SP; Simpson LL; Taylor RP; Dessain SK
    Mol Immunol; 2014 Feb; 57(2):247-54. PubMed ID: 24184879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protective potential of recombinant non-purified botulinum neurotoxin serotypes C and D.
    Moreira C; da Cunha CE; Moreira GM; Mendonça M; Salvarani FM; Moreira ÂN; Conceição FR
    Anaerobe; 2016 Aug; 40():58-62. PubMed ID: 27236078
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression, purification and characterization of the receptor-binding domain of botulinum neurotoxin serotype B as a vaccine candidate.
    Ben David A; Torgeman A; Barnea A; Zichel R
    Protein Expr Purif; 2015 Jun; 110():122-9. PubMed ID: 25727047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isolation and characterization of Hc-targeting chimeric heavy chain antibodies neutralizing botulinum neurotoxin type B.
    Jiang Y; Wang R; Guo J; Cheng K; Chen L; Wang X; Li Y; Du P; Gao C; Lu J; Yu Y; Yang Z
    Front Immunol; 2024; 15():1380694. PubMed ID: 38779676
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fully Human Monoclonal Antibodies Effectively Neutralizing Botulinum Neurotoxin Serotype B.
    Matsumura T; Amatsu S; Misaki R; Yutani M; Du A; Kohda T; Fujiyama K; Ikuta K; Fujinaga Y
    Toxins (Basel); 2020 May; 12(5):. PubMed ID: 32392791
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors.
    Yu YZ; Guo JP; An HJ; Zhang SM; Wang S; Yu WY; Sun ZW
    Vaccine; 2013 May; 31(20):2427-32. PubMed ID: 23583890
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.
    Shone C; Agostini H; Clancy J; Gu M; Yang HH; Chu Y; Johnson V; Taal M; McGlashan J; Brehm J; Tong X
    Infect Immun; 2009 Jul; 77(7):2795-801. PubMed ID: 19398544
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High level expression, purification and immunogenicity analysis of a protective recombinant protein against botulinum neurotoxin type E.
    Valipour E; Moosavi ML; Amani J; Nazarian S
    World J Microbiol Biotechnol; 2014 Jun; 30(6):1861-7. PubMed ID: 24469548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protective efficacy of recombinant bacterin vaccine against botulism in cattle.
    Moreira C; Ferreira MRA; Finger PF; Magalhães CG; Cunha CEP; Rodrigues RR; Otaka DY; Galvão CC; Salvarani FM; Moreira ÂN; Conceição FR
    Vaccine; 2020 Mar; 38(11):2519-2526. PubMed ID: 32037222
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intradermal immunization with botulinum neurotoxin serotype E DNA vaccine induces humoral and cellular immunity and protects against lethal toxin challenge.
    Kim NY; Ahn HB; Yu CH; Song DH; Hur GH; Shin YK; Shin S
    Hum Vaccin Immunother; 2019; 15(2):412-419. PubMed ID: 30235058
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Neutralization mechanism of human monoclonal antibodies against type B botulinum neurotoxin.
    Matsumura T; Kitamura M; Amatsu S; Yamaguchi A; Kobayashi N; Yutani M; Fujinaga Y
    Microbiol Immunol; 2024 Oct; 68(10):348-358. PubMed ID: 39239735
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Enhancing the protective immune response against botulism.
    Przedpelski A; Tepp WH; Kroken AR; Fu Z; Kim JJ; Johnson EA; Barbieri JT
    Infect Immun; 2013 Jul; 81(7):2638-44. PubMed ID: 23670557
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vaccination of cattle with a recombinant bivalent toxoid against botulism serotypes C and D.
    Cunha CE; Moreira GM; Salvarani FM; Neves MS; Lobato FC; Dellagostin OA; Conceição FR
    Vaccine; 2014 Jan; 32(2):214-6. PubMed ID: 24252701
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Enhanced effects of DNA vaccine against botulinum neurotoxin serotype A by targeting antigen to dendritic cells.
    Chen BY; Zhou G; Li QL; Lu JS; Shi DY; Pang XB; Zhou XW; Yu YZ; Huang PT
    Immunol Lett; 2017 Oct; 190():118-124. PubMed ID: 28802641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Subunit vaccine efficacy against Botulinum neurotoxin subtypes.
    Henkel JS; Tepp WH; Przedpelski A; Fritz RB; Johnson EA; Barbieri JT
    Vaccine; 2011 Oct; 29(44):7688-95. PubMed ID: 21839134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins.
    Webb RP; Smith TJ; Wright PM; Montgomery VA; Meagher MM; Smith LA
    Vaccine; 2007 May; 25(21):4273-82. PubMed ID: 17395341
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of a potential trivalent vaccine based on Hc fragments of botulinum toxins A, B, and E produced in a cell-free expression system.
    Zichel R; Mimran A; Keren A; Barnea A; Steinberger-Levy I; Marcus D; Turgeman A; Reuveny S
    Clin Vaccine Immunol; 2010 May; 17(5):784-92. PubMed ID: 20357058
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sublingual immunization with adenovirus F protein-based vaccines stimulates protective immunity against botulinum neurotoxin A intoxication.
    Jun S; Clapp B; Zlotkowska D; Hoyt T; Holderness K; Maddaloni M; Pascual DW
    Int Immunol; 2012 Feb; 24(2):117-28. PubMed ID: 22207133
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunological Characterization and Neutralizing Ability of Monoclonal Antibodies Directed Against Botulinum Neurotoxin Type H.
    Fan Y; Barash JR; Lou J; Conrad F; Marks JD; Arnon SS
    J Infect Dis; 2016 May; 213(10):1606-14. PubMed ID: 26936913
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.